|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Ukraine
Espicom Business Intelligence Ltd, Sep 2009, Pages: 58
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
Ukraine is the second largest country in Europe and the 22nd largest in the world. The population is estimated at 45.8 million in 2009. Ukraine aspires to join the EU, but currently Brussels will only consider negotiating agreements on free trade and visa facilitation. Relations with Russia remain complex; they have become more strained by Ukraine’s dependence on gas imports from the federation and recent price hikes.
Healthcare funding in Ukraine is largely through taxation. However, a system of public healthcare insurance has been under discussion since at least 1996. Government health expenditure is very low, even by Eastern European standards. Ukraine spends around 7.0% of GDP on healthcare, which is one of the lowest levels in Europe. Healthcare should be free for the whole population, but due to a lack of funding, patients are usually forced to make under-the-table payments.
In 2008, the Ukrainian market for pharmaceuticals was estimated at US$2,151 million, or US$47 per capita. It is expected that the pharmaceutical market will continue to expand at a rate of 9.1% per annum to reach US$3,326 million, equal to US$74 per capita, by 2013.
Around 72% of the pharmaceutical market is supplied by imports. Germany and India were the leading suppliers in 2006, accounting for over 30% of imports. Foreign companies dominate the market in value terms, as domestic producers focus on the production of low-priced generics.
In 2008, the USTR lowered Ukraine from its Priority Watch List, to the standard Watch List, due to improvements in IPR protection. In 2006, Ukraine amended its Law on Medicines to provide protection against unfair commercial use of pharmaceutical data submitted in the marketing approval process. IPR protection was strengthened as part of Ukraine’s bid to gain entry to the WTO; the country became a member in May 2008.
A small number of companies have updated their facilities to comply with GMP standards. The government changed the deadline for GMP compliance from 2002 to 2007, but full adaptation is not expected until 2011.
Customers who bought this item also bought
The Medical Device Market: Ukraine
The Pharmaceutical Market: Russia
Pharmaceutical Market in Ukraine 2008: Development Forecasts for 2008 - 2010
The Pharmaceutical Market: UK
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Netherlands
The Pharmaceutical Market: Romania
The Pharmaceutical Market: Bulgaria
The Pharmaceutical Market: Colombia
The Pharmaceutical Market: Argentina
The Pharmaceutical Market: Portugal
The Pharmaceutical Market: Morocco
|
|
|
|
